title: Comparison of somatostatin and vasopressin in bleeding esophageal varices.
abstract: Somatostatin (ST) and vasopressin (VP) infusions were compared in the treatment of actively bleeding esophageal varices. Fifty-four patients with liver cirrhosis were included in the study. Thirty-two were given ST 4.2 micrograms/min, and 22 patients were given VP 0.4 IU/min for 72 h after endoscopic diagnosis. The role of alcoholic cirrhosis was similar in both groups. Initial control of bleeding was achieved significantly more often (p = 0.0281) when ST was used (84.4%) than during VP treatment (57.1%). Rebleeding occurred in 18.8% and 4.8%, respectively. Side effects of treatment were significantly more common when VP was used than during ST treatment (p = 0.0021). Overall mortality was high in both groups, being 34% in the ST group and 36% in the VP group. ST infusion seems to be more effective and safer than VP in the treatment of acute variceal bleeding. However, the high frequency of rebleeding during ST treatment means that, after primary hemostasis with ST infusion, other methods, such as surgery or sclerotherapy, are needed to prevent the serious complications of rebleeding.
authors.affiliation: First Department of Surgery, Helsinki University Central Hospital, Finland.
authors.forename: A
authors.initials: A
authors.lastname: Saari
authors.forename: E
authors.initials: E
authors.lastname: Klvilaakso
authors.forename: M
authors.initials: M
authors.lastname: Inberg
authors.forename: M
authors.initials: M
authors.lastname: Pääkkönen
authors.forename: J
authors.initials: J
authors.lastname: Lahtinen
authors.forename: K
authors.initials: K
authors.lastname: Höckerstedt
authors.forename: T
authors.initials: T
authors.lastname: Schröder
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004932:Esophageal and Gastric Varices / Q000150:complications* / Q000401:mortality; D005260:Female; D005387:Finland / Q000453:epidemiology; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012008:Recurrence; D013004:Somatostatin / Q000009:adverse effects / Q000627:therapeutic use*; D014667:Vasopressins / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014667:Vasopressins; D013004:Somatostatin